Glycerol phenylbutyrate, sold under the brand name Ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. The medication works by preventing the harmful buildup of ammonia in the body.[2] It is an FDA-approved prescription drug in the US.[3] It was developed by Hyperion Therapeutics based on the existing medication sodium phenylbutyrate, and received approval in February 2013.[4]
Clinical data | |
---|---|
Trade names | Ravicti |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
License data |
|
Routes of administration | By mouth |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.228.552 |
Chemical and physical data | |
Formula | C33H38O6 |
Molar mass | 530.661 g·mol−1 |
3D model (JSmol) |
|
| |
|
Hyperion has been criticized for setting a high price for the drug. The price was set at US$250,000–290,000. In 2014, the drug generated $30.8 million in net sales, far behind the older and less expensive Buphenyl ($113.6 million in sales).[5]